MindMed to Commence Groundbreaking LSD Microdosing Study Evaluating Benefits on Neuroplasticity, Sleep, Cognitive Enhancement Variables and Immune System Response on the Human Body
The ATAI Life Sciences IPO could come as soon as the end of January. What does this mean for psychedelic stock investors?
MindMed closes on a CAD$92.1 million financing from what was originally a $50 million offering. Total cash on hand increases to US$144.4 million.
NEW YORK, Jan. 7, 2021 /PRNewswire/ -- Among the popular fields of study for biotech companies in recent years are gene editing, tissue engineering and regeneration, nanobiotechnology and others.
BetterLife Pharma Inc tapped the experience of psychedelic pioneer Hattie Wells to join its new psychedelic research advisory board.